Почетна › Плоскоклеточни карцином главе и врата › Орегон
Kliničke studije za Плоскоклеточни карцином главе и врата u državi Орегон
19 studija za Плоскоклеточни карцином главе и врата traži učesnike na lokacijama u državi Орегон.
Gradovi u državi Орегон
Zvanični tekst studije (na engleskom)
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- Providence Newberg Medical Center, Newberg
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Тражи се учесникФаза 2
Узраст од 18 до 79 · Оба пола · Ажурирано 12. 11. 2026. · NCT04671667BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- Providence Newberg Medical Center, Newberg
- и још 4
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT05136196Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Willamette Falls Medical Center, Oregon City
- Providence Portland Medical Center, Portland
- и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06589804A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Oregon Health And Science University, Portland
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07276399JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- Oregon Health And Science University, Portland
Тражи се учесникФаза 3
Узраст 60 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT04892173FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Providence Portland Medical Center (Site #0113), Portland
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06788990DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA15-0, Portland
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06953089A Study of MGC026 in Participants With Advanced Solid Tumors
- Providence Cancer Institute, Portland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06242470Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
- Oregon Health and Science University, Portland
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06980038Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
- OHSU Knight Cancer Institute, Portland
Тражи се учесникФаза 4
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT07405086Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #51, Portland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT05176483A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 02, Portland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 30. 9. 2026. · NCT07814248A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 6, Portland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 30. 9. 2026. · NCT07085091A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Portland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 29. 9. 2026. · NCT05877599Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- и још 8
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 14. 9. 2026. · NCT02734537Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- Clackamas Radiation Oncology Center, Clackamas
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 17. 8. 2026. · NCT04333537A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 17. 8. 2026. · NCT04895709First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Providence Cancer Institute Franz Clinic, Portland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 7. 7. 2026. · NCT05768139A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Providence Cancer Institute Franz Clinic, Portland
- Providence Oncology and Hematology Care Clinic - Westside, Portland
- Providence St. Vincent Medical Center- Investigational Drug Services, Portland
- и још 1
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 6. 7. 2026. · NCT04389632Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.